



The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

**Drug Advisory Committee January 2023 Meeting Outcome**

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection <sup>1</sup>
1	Acalabrutinib	Calquence	Malignant disease and immunosuppression	Approved	
2	Adalimumab	Humira	Skin	Approved	
3	Avelumab	Bavencio	Malignant disease and immunosuppression	Approved	
4	Burosumab	Crysvita	Endocrine system	Pending	Pending further information
5	Crisaborole	Staquis	Skin	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
6	Enzalutamide	Xtandi	Malignant disease and immunosuppression	Approved	
7	Erdafitinib	Balversa	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patient population
8	Gilteritinib	Xospata	Malignant disease and immunosuppression	Approved	
9	Human C1-esterase inhibitor	Beriner	Respiratory system	Approved	
10	Isatuximab	Sarclisa	Malignant disease and immunosuppression	Pending	Pending further information
11	Nintedanib	Ofev	Respiratory system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
12	Nivolumab	Opdivo	Malignant disease and immunosuppression	Approved	
13	Nivolumab / Ipilimumab	Opdivo / Yervoy	Malignant disease and immunosuppression	Approved	
14	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
15	Pemigatinib	Pemazyre	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patients population
16	Pertuzumab / Trastuzumab	Phesgo	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
17	Ravulizumab	Ultomiris	Nutrition and blood	Pending	Pending further information
18	Ripretinib	Qinlock	Malignant disease and immunosuppression	Pending	Pending further information
19	Siltuximab	Sylvant	Malignant disease and immunosuppression	Pending	Pending further information

	<b>Generic name</b>	<b>Brand name</b>	<b>Therapeutic Class</b>	<b>Meeting outcome</b>	<b>Primary reason for rejection<sup>1</sup></b>
20	Sodium zirconium cyclosilicate	Lokelma	Nutrition and blood	Approved	
21	Sotorasib	Lumakras	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patient population
22	Tucatinib	Tukysa	Malignant disease and immunosuppression	Pending	Pending further information
23	Upadacitinib	Rinvoq	Skin	Pending	Pending further information
24	Vericiguat	Verquvo	Cardiovascular system	Rejected	Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patient population

<sup>1</sup> The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.